- At the time of abstract data cutoff, COM701+ nivolumab +
BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall
response rate and 40% disease control rate in heavily pretreated
patients with platinum resistant ovarian cancer and was well
tolerated, with all responders remaining on therapy
- Longer follow up data will be included in the posters available
on ESMO Immuno-Oncology Congress 2022 (ESMO-IO) virtual platform on
December 6, 2022
- Management will discuss the preliminary data to be presented as
posters at ESMO-IO during an investor call planned for Wednesday, December 7, 2022, at 8:30 am ET
HOLON, Israel, Dec. 1, 2022
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage
cancer immunotherapy company and a pioneer in computational target
discovery, announced today publication of abstracts by ESMO-IO
showing that at the time of abstract data cutoff, Compugen's COM701
(anti-PVRIG) in dual and triple combination with nivolumab ±
BMS-986207 demonstrated preliminary anti-tumor activity and immune
activation in platinum resistant ovarian cancer patients and was
well tolerated.
The Company plans to host a conference call and webcast on
Wednesday, December 7, 2022, at
8:30 AM ET to review its preliminary
clinical data from dual and triple combination of COM701+ nivolumab
± BMS-986207 in platinum resistant ovarian cancer patients and its
COM701 ± nivolumab in metastatic NSCLC patients to be presented at
ESMO-IO, December 8, 2022,
Geneva, Switzerland. Abstracts are
available today on the ESMO-IO website and posters with longer
follow-up data will be available on the ESMO-IO virtual platform,
in the e-Poster section on December 6, 2022.
"Platinum resistant ovarian cancer patients are in urgent need
of new treatment options. Current standard of care, single agent
chemotherapy, is characterized by toxicity and low activity and
recently approved ADC therapy is restricted to a subset of the
population and limited by ocular toxicity. So far immune checkpoint
inhibitors showed limited activity especially in PD-L1 low
expressors, where the unmet need is the greatest," said
Anat Cohen-Dayag, Ph.D., President,
and CEO of Compugen. "At ESMO-IO we will present encouraging
preliminary anti-tumor activity supported by immune activation and
favorable safety profile following the dual and triple blockade of
PVRIG, PD-1 ± TIGIT in platinum resistant ovarian cancer patients.
The full data to be presented at the conference remain under
embargo until December 6, 2022 and
will contain longer follow up. We are looking forward to discussing
this data along with our NSCLC data which will also be presented at
ESMO-IO, in addition to our plans going forward, during our
investor call on December 7,
2022."
The abstracts are published today on the ESMO-IO website, and
the publication section of Compugen's website. On December 6, 2022, posters with longer follow-up
data will be available on the e-Poster section of the ESMO-IO
virtual platform and the publication section of Compugen's
website.
To access the Wednesday, December 7,
2022, 8:30 am ET live
conference call by telephone, please dial 1-866-744-5399 from the
U.S., or +972-3-918-0644 internationally. The call will be
available via live webcast through Compugen's website, located at
the following link. Following the live webcast, a replay will be
available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Partnered
programs include bapotulimab, an antibody targeting ILDR2, in Phase
1 development, licensed to Bayer under a research and discovery
collaboration and license agreement, and a TIGIT/PD-1 bispecific
derived from COM902 (AZD2936) in Phase 2 development by AstraZeneca
through a license agreement for the development of bispecific and
multi-specific antibodies. In addition, the Company's
therapeutic pipeline of early-stage immuno-oncology programs
consists of programs aiming to address various mechanisms of immune
resistance, including myeloid targets. The most advanced program,
COM503 is about to enter pre-IND enabling studies. COM503 is a
potential first-in-class, high affinity antibody targeting cytokine
biology to enhance anti-tumor immunity in a differentiated manner.
Compugen is headquartered in Israel, with offices in South San Francisco,
CA. Compugen's shares are listed on Nasdaq and the Tel
Aviv Stock Exchange under the ticker symbol CGEN.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended, and the safe-harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on the current beliefs,
expectations, and assumptions of Compugen. Forward-looking
statements can be identified using terminology such as "will,"
"may," "expects," "anticipates," "believes," "potential," "plan,"
"goal," "estimate," "likely," "should," "confident," and "intends,"
and similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements include, but are not limited to, statements regarding
Compugen's plan to present data at ESMO-IO with longer follow up.
These forward-looking statements involve known and unknown risks
and uncertainties that may cause the actual results, performance,
or achievements of Compugen to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Among these risks: the effect of
the global COVID-19 pandemic may negatively impact the global
economy and may also adversely affect Compugen's business and
operations; Clinical trials of any product candidates that
Compugen, or any current or future collaborators, may develop may
fail to satisfactorily demonstrate safety and efficacy to the FDA,
and Compugen, or any collaborators, may incur additional costs or
experience delays in completing, or ultimately be unable to
complete, the development and commercialization of these product
candidates; Compugen's business model is substantially dependent on
entering into collaboration agreements with third parties and
Compugen may not be successful in generating adequate revenues or
commercializing aspects of its business model. Compugen's approach
to the discovery of therapeutic products is based on its
proprietary computational target discovery infrastructure, which is
unproven clinically; and Compugen does not know whether it will be
able to discover and develop additional potential product
candidates or products of commercial value. These risks and other
risks are more fully discussed in the "Risk Factors" section of
Compugen's most recent Annual Report on Form 20-F as filed with the
Securities and Exchange Commission (SEC) as well as other documents
that may be subsequently filed by Compugen from time to time with
the SEC. In addition, any forward-looking statements represent
Compugen's views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Compugen does not assume any obligation to update any
forward-looking statements unless required by law.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugens-com701-anti-pvrig-in-dual-and-triple-combination-demonstrates-preliminary-anti-tumor-activity-and-immune-activation-in-platinum-resistant-ovarian-cancer-patients-301691144.html
SOURCE Compugen Ltd.